AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Barclays Maintains Buy Rating for PTC with $233 Price Target
ByAinvest
Thursday, Jul 31, 2025 7:54 am ET1min read
PTC (NASDAQ: PTC) received a new Buy recommendation from Barclays' Saket Kalia, with a price target of $233.00. The company's shares closed at $202.51. Kalia has a 5-star rating with an average return of 17.1% and a 64.62% success rate. PTC also received a Buy from KeyBanc's Jason Celino, but a Hold rating from Citi. The company has a one-year high of $213.14 and a one-year low of $133.38, with an average volume of 1.08M.
PTC Therapeutics (NASDAQ: PTC) has received a new Buy recommendation from Barclays' Saket Kalia, with a price target of $233.00. The company's shares closed at $202.51 on July 2, 2025. Kalia, who has a 5-star rating with an average return of 17.1% and a 64.62% success rate, has raised the target price from $46.00 to $233.00, indicating significant optimism in the company's future prospects [1].The new recommendation comes as PTC Therapeutics continues to show strong performance, with a one-year high of $213.14 and a one-year low of $133.38. The company has also seen increased institutional trading, with several investors and hedge funds raising their stakes in the stock [1].
In addition to Barclays, KeyBanc's Jason Celino has also issued a Buy rating for PTC Therapeutics, while Citi has given a Hold rating. The company's average trading volume is 1.08 million shares, reflecting its growing popularity among investors [1].
On the earnings front, PTC Therapeutics reported strong results for Q3 2025, with constant currency ARR growth of 9.3% and free cash flow growth of 14% year-over-year. The company's CEO, Neil Barua, highlighted the importance of AI-driven digital transformation and the deepening partnership with NVIDIA [2].
Overall, the new Buy recommendations from Barclays and KeyBanc, along with the company's strong earnings performance, suggest that PTC Therapeutics is well-positioned for continued growth. However, investors should also consider the company's debt levels and the potential impact of policy and trade uncertainty on its deal pacing.
References:
[1] https://www.marketbeat.com/instant-alerts/barclays-forecasts-strong-price-appreciation-for-ptc-therapeutics-nasdaqptct-stock-2025-07-29/
[2] https://seekingalpha.com/news/4475067-ptc-signals-8-percent-to-9-percent-arr-growth-guidance-for-q4-while-emphasizing-ai-and-go-to
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet